Exact Sciences' Screening segment's second-quarter performance is expected to have benefited from a continued increase in Cologuard volume. Per the last-reported quarter's earnings call, roughly 273,000 healthcare providers ordered Cologuard since its launch, with 9,000 new orders received in the first quarter. The segment is also likely to gain from revenue contributions from Cologuard rescreening in Q2. To address the substantial increase in colorectal cancer prevalence, the company made consistent efforts to raise awareness about screening individuals every three years, starting at age 45.